Contents 6 min reading

What changes, and what should be distinguished?

Neuroplasticity describes structural and functional changes in the nervous system associated with experience, activity or injury. Synaptic transmission, dendritic spines, circuit recruitment and learned behaviour are studied at different levels. Change at one level does not automatically establish another: improvement on a memory test does not demonstrate new neuron formation, and a cellular image does not establish better everyday memory.

Plasticity should not be treated as an inherently beneficial increase. Strengthening, weakening and reorganisation must be interpreted in context. “More connections” or “higher BDNF” alone is not a success criterion. The useful research question is which change accompanies a meaningful functional result, on which task, in which population, and for how long. These distinctions prevent an appealing biological story from becoming a promise of general enhancement.

LTP and LTD: synaptic strength without a promise of permanence

Long-Term Potentiation (LTP) is an experimentally measured, sustained increase in synaptic response after a particular stimulation pattern; “long-term” does not mean permanent. At some hippocampal synapses, NMDA receptors, calcium signalling and changes involving AMPA receptors are important mechanisms. Not all LTP has identical mechanisms. The narrative review by Bliss and Collingridge presents a model of memory, rather than directly measuring every human memory.

Long-Term Depression (LTD) is a sustained reduction in synaptic transmission. It is distinct from pruning, the anatomical elimination of a connection. LTP and LTD describe experimental forms of activity-dependent adjustment. Neither a supplement’s interaction with an LTP-related pathway nor an illustration displaying additional receptors proves improved learning in a person. The experimental preparation, stimulation protocol and behavioural outcome remain essential to interpretation.

Conceptual depiction of two axon terminals and dendritic spines separated by synaptic clefts.
AI-generated conceptual illustration. This is not microscopy, measured LTP or evidence of a compound’s effect.

BDNF and NGF: the gap between mechanism and measurement

BDNF and NGF are neurotrophic signalling proteins that influence neuronal survival, development and synaptic function in cell-specific and context-dependent ways. Calling them “brain fertiliser” hides this complexity. The BDNF review by Lu and colleagues discusses mechanisms and disease associations; it is not a clinical trial establishing a BDNF target or supplement dose for healthy people. A plausible mechanism supplies a research question, not a treatment indication.

Blood BDNF is not a direct measurement of BDNF activity in a particular brain region. Sample type, including serum versus plasma, and collection and processing methods matter. A biomarker change is a different outcome from improved daily function. A higher value cannot automatically be interpreted as better. This guide therefore offers no target for “BDNF optimisation”, testing schedule or inference that a blood result verifies brain regeneration. Naegelin et al., 2018; Amadio et al., 2017.

Adult neurogenesis is a separate research question

New neuron formation is separate from changes in existing synapses. Human hippocampal tissue studies by Sorrells and colleagues (2018) and Boldrini and colleagues (2018) reached different conclusions about adult neurogenesis. Tissue preservation, marker selection and sample characteristics affect interpretation. These examples do not resolve the entire current debate or establish a constant lifelong rate. Neither demonstrates that a consumer product produces new neurons in living people.

Exercise and learning in humans: what is measured?

The randomised trial by Erickson and colleagues (2011) compared one year of aerobic exercise with stretching in 120 older adults. Hippocampal volume increased by about 2% in the exercise group. MRI volume is an anatomical outcome, not a count of newly generated neurons or proof of dementia prevention. Removing the population, comparator and follow-up period turns a specific result into an unjustified universal “brain growth” claim.

The narrative review by Voss and colleagues considers links between animal mechanisms and human exercise findings; it does not supply a meta-analytic pooled effect. Cognitive tasks, imaging and blood measurements answer different questions. Even when they change together in one study, this alone does not establish that blood BDNF caused a memory change. Demonstrating that a mechanism mediates an outcome requires more than correlation.

Improvement on a practised task should be distinguished from transfer to untrained tasks. A faster game score is not equivalent to general intelligence or independence in daily life. Persistence requires measurement after training ends. Sleep and stress are relevant considerations in learning research, but they do not justify saying that everyone’s hippocampus shrinks under stress or that particular habits guarantee neurogenesis. Individual symptoms and health circumstances cannot be reduced to one biomarker.

Nootropic claims: the product and outcome matter

Mori and colleagues (2009) randomised 30 people with mild cognitive impairment in a 16-week double-blind, placebo-controlled trial; 29 were analysed after one participant withdrew. The research product provided 3 g of tablets daily containing 96% dried Hericium erinaceus powder. Differences on a cognitive rating scale were reported. This does not demonstrate increased NGF, synaptic rebuilding or dementia prevention in humans. The small sample limits generalisation to all products or healthy younger adults.

The magnesium L-threonate experiments by Slutsky and colleagues (2010) examined learning, memory and synaptic measures in rats. This preclinical study does not establish the same effect size, dose or safety profile in humans. Translating a brain-magnesium hypothesis into clinical advice requires evaluation of the actual product, cognitive outcomes and adverse effects in the relevant human population. Directly converting an animal dose into a human dose does not close that gap.

Lion’s Mane, Bacopa monnieri and magnesium L-threonate do not constitute one established class of “plasticity boosters”. Species, plant or mushroom part, extraction and standardisation define the research product. A cognitive finding for one formulation does not transfer to another. This guide’s sources establish neither comparative efficacy nor combination safety or general plasticity benefits in healthy people. An absent interaction record is not evidence that a combination is safe.

How to read a plasticity claim

First identify the design. Cell experiments can investigate pathway hypotheses; animal experiments investigate preclinical effects in an organism. Observational human studies can show associations but face confounding when interpreting causality. A randomised controlled trial tests a defined intervention against a comparator. A systematic review uses specified search and selection methods; a meta-analysis combines suitable study results. None of these labels by itself removes small samples, bias or outcomes that have little clinical relevance.

Then read the population, product, comparator, measured outcome and follow-up together. The size and uncertainty of a possible benefit, withdrawals and adverse events matter; “statistically significant” is insufficient on its own. Assessing symptoms or loss of function is different from trying to increase a plasticity score. These findings supply no instruction to start a supplement, change treatment, combine products or set a personal dose. Better research questions make claims more interpretable without guaranteeing a benefit.

Sources

  1. Lu B, Nagappan G, Lu Y. (2014). BDNF and synaptic plasticity, cognitive function, and dysfunction. Handbook of Experimental Pharmacology, 220, 223–250. PubMed · PMID 24668475
  2. Bliss TV, Collingridge GL. (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31–39. PubMed · PMID 8421494
  3. Mori K, et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372. PubMed · PMID 18844328
  4. Slutsky I, et al. (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165–177. PubMed · PMID 20152124
  5. Voss MW, et al. (2013). Bridging animal and human models of exercise-induced brain plasticity. Trends in Cognitive Sciences, 17(10), 525–544. PubMed · PMID 24029446

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions